title: Competency to consent to medical treatment in cognitively impaired patients with Parkinson's disease.
abstract: OBJECTIVE
  To investigate capacity to consent to medical treatment (competency) in cognitively impaired patients with PD.
  
  
  BACKGROUND
  Although competency has been studied empirically in patients with cortical dementia (AD), no empirical studies have examined competency in patients with PD or other subcortical neurodegenerative disorders.
  
  
  METHODS
  Patients with PD with cognitive impairment (n = 20) and older controls (n = 20) were compared using a standardized competency measure (Capacity to Consent to Treatment Instrument [CCTI]) and neuropsychological test measures. The CCTI tests competency performance and assigns outcomes (capable, marginally capable, incapable) under four different legal standards (LS).
  
  
  RESULTS
  Patients with PD performed below controls on the four LS: capacity to evidence a treatment choice (LS1) (p < 0.03), capacity to appreciate consequences of a treatment choice (LS3) (p < 0.03), capacity to provide rational reasons for a treatment choice (LS4) (p < 0.0001), and capacity to understand the treatment situation and choices (LS5) (p < 0.0001). With respect to competency outcomes, patients with PD demonstrated increasing compromise (marginally capable or incapable outcomes) across the four standards: LS1 (25%), LS3 (45%), LS4 (55%), and LS5 (80%). In the PD group, simple measures of executive function (the Executive Interview) and to a lesser extent memory/orientation (Dementia Rating Scale, Memory subscale) were key predictors of competency performance and outcome on the LS.
  
  
  CONCLUSIONS
  Cognitively impaired patients with PD are likely to have impaired consent capacity, and are at risk of losing competency over the course of their neurodegenerative illness. Patients with PD have particular difficulty meeting more stringent, clinically relevant competency standards that tap reasoning skills and comprehension of treatment information. Executive dysfunction appears to be a primary neurocognitive mechanism for competency loss in PD.
authors.affiliation: Department of Psychiatry, University of Chicago, IL, USA.
authors.forename: M P
authors.initials: MP
authors.lastname: Dymek
authors.forename: P
authors.initials: P
authors.lastname: Atchison
authors.forename: L
authors.initials: L
authors.lastname: Harrell
authors.forename: D C
authors.initials: DC
authors.lastname: Marson
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003072:Cognition Disorders / Q000628:therapy*; D003144:Communication Barriers; D006801:Humans; D007258:Informed Consent / Q000331:legislation & jurisprudence / Q000706:statistics & numerical data*; D016743:Mental Competency / Q000331:legislation & jurisprudence; D008875:Middle Aged; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000628:therapy*; D011594:Psychometrics; D014481:United States